Amide α,β-Dehydrogenation Using Allyl-Palladium Catalysis and a Hindered Monodentate Anilide
摘要:
A practical and direct method for the alpha,beta-dehydrogenation of amides is reported using allyl-palladium catalysis. Critical to the success of this process was the synthesis and application of a novel lithium N-cyclohexyl anilide (LiCyan). The reaction conditions tolerate a wide variety of substrates, including those with acidic heteroatom nucleophiles.
Amide α,β-Dehydrogenation Using Allyl-Palladium Catalysis and a Hindered Monodentate Anilide
摘要:
A practical and direct method for the alpha,beta-dehydrogenation of amides is reported using allyl-palladium catalysis. Critical to the success of this process was the synthesis and application of a novel lithium N-cyclohexyl anilide (LiCyan). The reaction conditions tolerate a wide variety of substrates, including those with acidic heteroatom nucleophiles.
A series of novel indole derivatives was designed, synthesized and evaluated by cell-based assays for their inhibitory activities against 5-LOX in rat peritoneal leukocytes. Most of them (30 out of 35) showed an inhibitory potency higher than the initial screening hit 1a (IC50 = 74 mu M). Selected compounds for concentration-response studies showed prominent inhibitory activities with IC50 values ranging from 0.74 mu M to 3.17 mu M. Four compounds (1m, 1s, 4a, and 6a) exhibited the most potent inhibitory activity compared to that of the reference drug (Zileuton), with IC50 values less than I mu M. Molecular modeling studies for compounds 1a, 3a, 4a, and 6a were also presented. The excellent in vitro activities of this class of compounds may possess potential for the treatment of LT-related diseases. (C) 2007 Published by Elsevier Ltd.
[EN] SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES<br/>[FR] INHIBITEURS À PETITE MOLÉCULE D'HISTONE DÉSACÉTYLASES
申请人:NUPOTENTIAL INC
公开号:WO2013059582A2
公开(公告)日:2013-04-25
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment, the disclosure relates to small molecules for inhibiting the growth of cancer cells. In still another embodiment, the disclosure relates to small molecules for reprogramming a cell.